Pooraskari Z, Barri Ghazani H, Piri R, Habibi S, Shahidi M
Med Oncol. 2025; 42(4):107.
PMID: 40082344
DOI: 10.1007/s12032-025-02659-8.
Ganesan I, Kiyokawa H
Cancers (Basel). 2025; 17(4).
PMID: 40002221
PMC: 11853300.
DOI: 10.3390/cancers17040626.
Silva A, Bitencourt T, Vargas J, Fraga L, Filippi-Chiela E
Genet Mol Biol. 2024; 47Suppl 1(Suppl 1):e20230311.
PMID: 38805699
PMC: 11132560.
DOI: 10.1590/1678-4685-GMB-2023-0311.
Wang W, Albadari N, Du Y, Fowler J, Sang H, Xian W
Pharmacol Rev. 2024; 76(3):414-453.
PMID: 38697854
PMC: 11068841.
DOI: 10.1124/pharmrev.123.001026.
Alaseem A
Saudi Pharm J. 2023; 31(10):101790.
PMID: 37818252
PMC: 10561124.
DOI: 10.1016/j.jsps.2023.101790.
The Chemoprotective Potentials of Alpha-lipoic Acid against Cisplatin-induced Ototoxicity: A Systematic Review.
Al-Awsi G, Arshed U, Arif A, Ramirez-Coronel A, Alhassan M, Mustafa Y
Curr Med Chem. 2023; 31(23):3588-3603.
PMID: 37165582
DOI: 10.2174/0929867330666230509162513.
Involvement of Bcl-2 Family Proteins in Tetraploidization-Related Senescence.
Barriuso D, Alvarez-Frutos L, Gonzalez-Gutierrez L, Motino O, Kroemer G, Palacios-Ramirez R
Int J Mol Sci. 2023; 24(7).
PMID: 37047342
PMC: 10094710.
DOI: 10.3390/ijms24076374.
MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia.
Lerma Clavero A, Boqvist P, Ingelshed K, Bosdotter C, Sedimbi S, Jiang L
Sci Rep. 2023; 13(1):4583.
PMID: 36941277
PMC: 10027891.
DOI: 10.1038/s41598-023-31484-0.
The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth and Potentiates Radiotherapy.
Ingelshed K, Spiegelberg D, Kannan P, Pavenius L, Hacheney J, Jiang L
Cancer Res Commun. 2023; 2(9):1075-1088.
PMID: 36922937
PMC: 10010373.
DOI: 10.1158/2767-9764.CRC-22-0053.
AMG-232, a New Inhibitor of MDM-2, Enhance Doxorubicin Efficiency in Pre-B Acute Lymphoblastic Leukemia Cells.
Ghotaslou A, Samii A, Boustani H, Kiani Ghalesardi O, Shahidi M
Rep Biochem Mol Biol. 2022; 11(1):111-124.
PMID: 35765530
PMC: 9208559.
DOI: 10.52547/rbmb.11.1.111.
A systematic review of the therapeutic effects of resveratrol in combination with 5-fluorouracil during colorectal cancer treatment: with a special focus on the oxidant, apoptotic, and anti-inflammatory activities.
Moutabian H, Majdaeen M, Ghahramani-Asl R, Yadollahi M, Gharepapagh E, Ataei G
Cancer Cell Int. 2022; 22(1):142.
PMID: 35366874
PMC: 8976963.
DOI: 10.1186/s12935-022-02561-7.
In Vitro and In Vivo Cardioprotective Effects of Curcumin against Doxorubicin-Induced Cardiotoxicity: A Systematic Review.
Zhang Q, Wu L
J Oncol. 2022; 2022:7277562.
PMID: 35237323
PMC: 8885194.
DOI: 10.1155/2022/7277562.
Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy.
Elbanna M, Chowdhury N, Rhome R, Fishel M
Front Oncol. 2021; 11:749496.
PMID: 34733787
PMC: 8558533.
DOI: 10.3389/fonc.2021.749496.
A Systematic Review of the Potential Chemoprotective Effects of Resveratrol on Doxorubicin-Induced Cardiotoxicity: Focus on the Antioxidant, Antiapoptotic, and Anti-Inflammatory Activities.
Hu L, Lan H, Li X, Jin K
Oxid Med Cell Longev. 2021; 2021:2951697.
PMID: 34471463
PMC: 8405305.
DOI: 10.1155/2021/2951697.
Screening and Validation of Molecular Targeted Radiosensitizers.
Willers H, Pan X, Borgeaud N, Korovina I, Koi L, Egan R
Int J Radiat Oncol Biol Phys. 2021; 111(5):e63-e74.
PMID: 34343607
PMC: 8602724.
DOI: 10.1016/j.ijrobp.2021.07.1694.
MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy.
Miles X, Vandevoorde C, Hunter A, Bolcaen J
Front Oncol. 2021; 11:703442.
PMID: 34307171
PMC: 8296304.
DOI: 10.3389/fonc.2021.703442.
Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors.
LaPlante G, Zhang W
Cancers (Basel). 2021; 13(12).
PMID: 34203106
PMC: 8235664.
DOI: 10.3390/cancers13123079.
MDM2 inhibition: an important step forward in cancer therapy.
Konopleva M, Martinelli G, Daver N, Papayannidis C, Wei A, Higgins B
Leukemia. 2020; 34(11):2858-2874.
PMID: 32651541
DOI: 10.1038/s41375-020-0949-z.
Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
Shattuck-Brandt R, Chen S, Murray E, Johnson C, Crandall H, ONeal J
Clin Cancer Res. 2020; 26(14):3803-3818.
PMID: 32234759
PMC: 7367743.
DOI: 10.1158/1078-0432.CCR-19-1895.
A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma.
Yi H, Yan X, Luo Q, Yuan L, Li B, Pan W
J Exp Clin Cancer Res. 2018; 37(1):97.
PMID: 29716622
PMC: 5930807.
DOI: 10.1186/s13046-018-0765-8.